Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSKGlobeNewsWire • 01/24/22
Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies for Solid TumorsGlobeNewsWire • 12/16/21
Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical ProgramsGlobeNewsWire • 12/15/21
Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 11/12/21
Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 08/12/21